Genetic and clinical factors influence the baseline permeability of the peritoneal membrane

Kidney International

Volumn 67, Issue 6, 2005, Pages 2477-2487

  Gillerot, Gaëlle ^b   Goffin, Eric ^b   Michel, Catherine ^b   Evenepoel, Pieter ^b   Van Biesen, Wim ^b   Tintillier, Michel ^b   Stenvinkel, Peter ^b   Heimbürger, Olof ^b   Lindholm, Bengt ^b   Nordfors, Louise ^b   Robert, Annie ^b   Devuyst, Olivier ^a  

^a UCL   (Belgium)

^b NONE

Author keywords

Inflammation; Interleukin 6; Peritoneal dialysis; Pet; Polymorphisms

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; SERUM ALBUMIN; VASCULOTROPIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ALLELE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SOLUTE; GENETICS; METABOLISM; MIDDLE AGED; PERITONEUM; PERMEABILITY; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23044486810     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00357.x     Document Type: Article

References (44)

1. TWARDOWSKI ZJ, NOLPH KD, KHANNA R, et al: Peritoneal equilibration test. Perit Dial Bull 7:138-147, 1987
2. CHURCHILL DN, THORPE KE, NOLPH KD, et al: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 9:1285-1292, 1998
3. DAVIES SJ, PHILLIPS L, GRIFFITHS AM, et al: What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207-2217, 1998
4. RODBY RA, FIRANEK CA, SARPOLIS AL: Re-evaluation of solute transport groups using the peritoneal equilibration test. Perit Dial Int 19:438-441, 1999
5. DAVIES SJ, PHILLIPS L, NAISH PF, RUSSEL GI: Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 17:1085-1092, 2002
6. MARGETTS P, CHURCHILL DN: Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 13:2787-2794, 2002
7. GILLEROT G, DEVUYST O: Changes in the peritoneal membrane with peritoneal dialysis: Molecular mechanisms. Clin Nephrol 60:1-6, 2003
8. KREDIET RT: The physiology of peritoneal solute transport and ultrafiltration, in Textbook of Peritoneal Dialysis, edited by Gokal R, Khanna R, Krediet RT, Nolph KD, Dordrecht, Kluwer Academic Publishers, 2000, pp 135-172
9. MIYATA T, DEVUYST O, KUROKAWA K, VAN YPERSELE DE STRIHOU C: Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61:375-386, 2002
10. FERRARA N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56:794-814, 1999
11. ZWEERS MM, DE WAART DR, SMIT W, et al: Growth factors VEGF and TGF-β in peritoneal dialysis. J Lab Clin Med 134:124-132, 1999
12. PECOITS-FILHO R, ARAUJO MR, LINDHOLM B, et al: Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 17:1480-1486, 2002
13. NAKA T, NISHIMOTO N, KISHIMOTO T: The paradigm of IL-6: from basic science to medicine. Arthritis Res 4:S233-S242, 2002
14. HURST SM, WILKINSON TS, MCLOUGHLIN RM, et al: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14:705-714, 2001
15. JONES SA, HORIUCHI S, TOPLEY N, et al: The soluble interleukin 6 receptor: Mechanisms of production and implications in disease. FASEB J 15:43-58, 2001
16. JORRES A, LUDAT K, LANG J, et al: Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines. J Am Soc Nephrol 7:2192-2201, 1996
17. KUBES P: Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation 2:235-244, 1995
18. MORBIDELLI L, DONNINI S, ZICHE M: Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 9:521-530, 2003
19. COMBET S, BALLIGAND JL, LAMEIRE N, et al: A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney Int 57:332-338, 2000
20. NI J, MOULIN P, GIANELLO P, et al: Mice lacking endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 14:3205-3216, 2003
21. MIYAMOTO Y, SAITO Y, KAJIYAMA N, et al: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32:3-8, 1998
22. WANG XL, SIM AS, BADENHOP RF, et al: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2:41-15, 1996
23. WATSON C, WEBB NJ, BOTTOMLEY MJ, BRENCHLEY PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 12:1232-1235, 2000
24. SHAHBAZI M, FRYER AA, PRAVICA V, et al: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260-264, 2002
25. FISHMAN D, FAULDS G, JEFFERY R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 level, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1102:1369-1376, 1998
26. FEDETZ M, MATESANZ F, PASCUAL M, et al: The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neur Sciences 190:69-72, 2001
27. WRIGHT LF: Survival in patients with end-stage renal disease. Am J Kidney Dis 17:25-28, 1991
28. SMIT W, LANGEDIJK MJ, SCHOUTEN N, et al: A comparison between 1.36% and 3.86% glucose dialysis solution for assessment of peritoneal membrane function. Perit Dial Int 20:734-741, 2000
29. WANIEWSKI J, HEIMBURGER O, WERYNSKI A, LINDHOLM B: Aqueous solute concentrations and evaluation of mass transport coefficients in peritoneal dialysis. Nephrol Dial Transplant 7:50-56, 1992
30. NORDFORS L, JANSSON M, SANDBERG G, et al: Large-scale genotyping of single nucleotide polymorphisms by Pyrosequencing and validation against the 5′ nuclease (Taqman) assay. Hum Mutat 19:395-401, 2002
31. PEIRSON SN, BUTLER JN, FOSTER RG: Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31:e73, 2003
32. LIN MT, STORER B, MARTIN PJ, et al: Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201-2210, 2003
33. PERSU A, STOENOIU MS, MESSIAEN T, et al: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Gen 11:229-241, 2002
34. CARDON LR, PALMER LJ: Population stratification and spurious allelic association. Lancet 361:598-604, 2003
35. PECOITS-FILHO R, BARANY P, LINDHOLM B, et al: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17:1684-1688, 2002
36. CHUNG SH, HEIMBURGER O, STENVINKEL P, et al: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 23:174-183, 2003
37. BRULL DJ, LEESON CP, MONTGOMERY HE, et al: The effect of the interleukin-6 -174G > C promoter gene polymorphism on endothelial function in healthy volunteers. Eur J Clin Invest 32:153-157, 2002
38. GAUDINO M, ANDREOTTI F, ZAMPARELLI R, et al: The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108(Suppl 1):195-199, 2003
39. DAVIES SJ: Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 66:2437-2445, 2004
40. BRULL DJ, MONTGOMERY HE, SANDERS J, et al: Interleukin-6 gene -174G/C and -572G/C promoter polymorphisms are strongly predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458-1463, 2001
41. LOSITO A, KALIDAS K, SANTONI S, JEFFERY S: Association of interleukin-6 -174G/C promoter polymorphisms with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64:616-622, 2003
42. KIECOLT-GLASER JK, PREACHER KJ, MACCALLUM RC, et al: Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 100:9090-9095, 2003
43. IOANNIDIS JPA: Genetic associations: False or true? Trends Mol Med 9:135-138, 2003
44. REBBECK TR, SPITZ M, Wu X: Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5:589-597, 2004